Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2024-08-12 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, regarding the loss of share certificate details received from a shareholder. It is addressed to stock exchanges and signed by the company secretary. The document is short (2876 characters) and is a regulatory compliance communication rather than a financial report or announcement of financial results. It does not contain financial data, earnings, management discussion, or other report content. It is not an announcement of voting results, board changes, or capital changes. It is a regulatory filing related to share certificate loss compliance under SEBI regulations, which fits best under Regulatory Filings (RNS).
2024-08-12 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
Regulatory Filings Classification · 90% confidence The document contains only placeholders for images and no textual content or financial data. It is extremely short (220 characters) and does not provide any report, announcement, or detailed information. There is no indication of the document type or any regulatory references. Given the lack of content, it cannot be classified as a substantive report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without clear classification.
2024-08-12 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the incorporation of a wholly owned subsidiary in New Zealand by Lupin Ltd. It details the incorporation, shareholding, and related party status of the new subsidiary Lupin NZ Ltd. The document is an announcement of a corporate event (incorporation of a subsidiary) and does not contain financial statements, earnings data, or detailed management discussion. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or audit report. It fits best under Capital/Financing Update (CAP) as it relates to corporate structure and capital changes through subsidiary incorporation. The document length is over 6000 characters and contains substantive information about the transaction, not just a brief notice or report publication announcement.
2024-08-08 English
Generic Health Pty Ltd., Australia, wholly owned subsidiary of Lupin Ltd., has incorporated Lupin NZ Ltd., New Zealand, as it wholly owned subsidiary.
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the incorporation of a wholly owned subsidiary, Lupin NZ Ltd., in New Zealand by Generic Health Pty Ltd., a wholly owned subsidiary of Lupin Ltd. The document provides detailed information about the new subsidiary, including its incorporation date, shareholding, business line, and regulatory compliance. There are no financial statements, earnings data, or management discussion of financial results. The document is an announcement of a corporate action related to capital structure (incorporation of a subsidiary) and related party transaction disclosures. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as incorporation of subsidiaries. The document length is over 6,000 characters and contains substantive information, not just a brief notice or report publication announcement. Therefore, the classification is CAP with high confidence.
2024-08-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short communication dated August 7, 2024, addressed to stock exchanges (BSE and NSE) regarding the audio recording of the Earnings Call for Q1 FY25. It references SEBI regulations for disclosure but does not contain any financial data or detailed transcript. The document provides a link to the audio recording rather than the transcript or detailed financial results. The length is only 1662 characters, indicating it is a brief announcement rather than a full report. According to the rules, announcements about earnings calls or reports that only provide links or state that recordings are hosted on the website should be classified as Regulatory Filings (RNS), not as Call Transcript (CT) or Earnings Release (ER).
2024-08-07 English
Audio recording of the Earnings Call - Q1 FY25
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about the hosting of the audio recording of the Earnings Call for Q1 FY25 on the company's website. It references the SEBI regulation for disclosure but does not contain the transcript or detailed financial data itself. The document is short (1648 characters) and serves as an announcement of the availability of the earnings call recording rather than the call transcript or financial report itself. According to the rules, such announcements about the availability of earnings call recordings should be classified as Regulatory Filings (RNS) because it is a general regulatory announcement and does not contain the full transcript or substantive financial data.
2024-08-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.